LLY

Eli Lilly shares are trading higher today, continuing a period of momentum that saw the stock reach a new 52-week high earlier in the session. This positive sentiment follows the company's selection by the FDA for a new pilot program designed to accelerate the review process for domestic pharmaceutical manufacturing facilities. The stock also continues to benefit from recent positive regulatory developments, including a favorable opinion from the European Medicines Agency for the cancer drug Jaypirca and the expansion of Medicare access for its weight-loss treatments.